PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Shaun D FontaineAngelo D SantiRalph ReidPhilip C SmithGary W AshleyDaniel V SantiPublished in: Cancer chemotherapy and pharmacology (2019)
The disposition of PEGylated SN-38 is independent of UGT1A activity in rats, and PLX038 may find utility in full-dose treatment of patients who are UGT1A1*28 homozygotes or have metastatic disease with coincidental or incidental liver dysfunction.